= user generated What's this?
This image provided by:
Kaplan–Meier plot of overall survival among all 1,092 resected pancreatic adenocarcinoma patients with (yellow line) and without (blue line) adjuvant chemoradiation therapy (P < .001)
As illustrated in Fig. 1, compared with those who underwent
surgery alone, adjuvant CRT improved survival with a RR of 0.73
(95% CI: 0.64–0.84) with longer median OS (15.5 vs.
Hsu, Charles C.; Herman, Joseph M.; Corsini, Michele M.; Winter, Jordan M.; Callister, Matthew D.; Haddock, Michael G.; Cameron, John L.; Pawlik, Timothy M.; Schulick, Richard D.; Wolfgang, Christopher L.; Laheru, Daniel A.; Farnell, Michael B.; Swartz, Michael J.; Gunderson, Leonard L.; Miller, Robert C.Journal: Annals of Surgical Oncology
Issue 4DOI: 10.1245/s10434-009-0743-7Published: 2010-03-16Institution(s):
Johns Hopkins Hospital, Mayo Clinic, Mayo Clinic Arizona, University of California, San Francisco
Survival for pancreatic ductal adenocarcinoma is low, the role of adjuvant therapy remains controversial, and recent data suggest adjuvant chemoradiation (CRT) may decrease survival compared with surgery alone. Our goal was to examine efficacy of adjuvant CRT in resected pancreatic adenocarcinoma compared with surgery alone.
Patients with pancreatic adenocarcinoma at Johns Hopkins Hospital (n = 794, 1993–2005) and Mayo Clinic (n = 478, 1985–2005) following resection who were observed (n = 509) or received adjuvant 5-FU based CRT (median dose 50.4 Gy; n = 583) were included. Cox survival and propensity score analyses assessed associations with overall survival. Matched-pair analysis by treatment group (1:1) based on institution, age, sex, tumor size/stage, differentiation, margin, and node positivity with N = 496 (n = 248 per treatment arm) was performed.
Median survival was 18.8 months. Overall survival (OS) was longer among recipients of CRT versus surgery alone (median survival 21.1 vs. 15.5 months, P < .001; 2- and 5-year OS 44.7 vs. 34.6%; 22.3 vs. 16.1%, P < .001). Compared with surgery alone, adjuvant CRT improved survival in propensity score analysis for all patients by 33% (P < .001), with improved survival when stratified by age, margin, node, and T-stage (RR = 0.57–0.75, P < .05). Matched-pair analysis demonstrated OS was longer with CRT (21.9 vs. 14.3 months median survival; 2- and 5-year OS 45.5 vs. 31.4%; 25.4 vs. 12.2%, P < .001).
Adjuvant CRT is associated with improved survival after pancreaticoduodenectomy. Adjuvant CRT was not associated with decreased survival in any risk group, even in propensity score and matched-pair analyses. Further studies evaluating adjuvant chemotherapy compared with adjuvant chemoradiation are needed to determine the most effective combination of systemic and local–regional therapy to achieve optimal survival results.
This image is from the article titled "Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study"
(from Annals of Surgical Oncology), which is copyrighted by The Author(s). For more information on the
copyright for this image, please refer to the full image caption and to the
This image is published with open access and made available for noncommercial purposes. For more information on what you are allowed to do with this image, please see the Creative Commons pages.
To request permissions to use any copyrighted material, please visit the source document.
Report a copyright concern regarding this image.
Log in or register to save your favorite images and download them as high-quality PowerPoint or PDF files.
Log in or register to save your search criteria.
© Springer, part of Springer Science+Business Media.
Remote Address: 126.96.36.199 Server: 21